FDA Oncologic Drug Committee Agrees That “Kitty Fight” With NCI Should Be Negotiated
In Brief: NCI Tells Cooperative Groups To Submit applications For Extra Multimodality Funds
FDA Delays NDA On BCNU, But New Drug Seminar Still Scheduled
Proposed Guidelines For Clinical Tests Of Oncologic Drugs
UCLA, NYU, Ohio States Must Wait Longer For Comprehensive Status
Contact Planned To Encourage Insurers To Reimburse For Cancer Screening
Rosemond Asks Ban On High Tar, Nicotine Cigarettes
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”